Recombinant oncolytic adenovirus based on PCV2 functional protein as well as preparation method and application of recombinant oncolytic adenovirus
By constructing a recombinant oncolytic adenovirus containing the PCV2 Cap and/or Rep genes, a multi-mechanism synergistic effect is achieved, solving the problems of single targeting, drug resistance, and difficulty in inhibiting tumor metabolism in existing oncolytic virus therapies, and achieving highly efficient tumor growth inhibition and reversal of chemotherapy resistance.
Patent Information
- Application Number
- CN202610008455.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-01-05
- Publication Date
- 2026-03-31
AI Technical Summary
Existing oncolytic virus therapies suffer from limited targeting, easy development of drug resistance, and difficulty in effectively inhibiting tumor metabolism and metastasis. Wild-type porcine circovirus type 2 (PCV2) has low infection efficiency and poses safety risks. Current technologies lack oncolytic virus agents with synergistic effects through multiple mechanisms.
A recombinant oncolytic adenovirus based on PCV2 functional proteins was constructed, containing the PCV2 Cap gene and/or Rep gene. Using a replication-defective adenovirus vector, a multi-mechanism synergistic effect was achieved, including activation of p53-mediated apoptosis, inhibition of stress granule formation, inhibition of tumor cell glycolysis metabolism, and reversal of chemotherapy resistance.
It significantly improved the tumor growth inhibition effect, and showed stronger anti-tumor activity than traditional single-mechanism oncolytic viruses in in vitro cell experiments and in vivo animal models. It can effectively reverse chemotherapy resistance and inhibit tumor metastasis.